Given that ErbB signaling can be tumor-permissive by negatively impacting anti-tumor immunity, it will also be of interest in future studies to determine whether ErbB/AKT co-targeting can be integrated with immune checkpoint inhibition to improve the treatment outcomes in PCa, which generally otherwise is minimally responsive to an immune checkpoint blockade [68]. The gene discussed is EGFR; the disease is neoplasm.